In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo Co. Ltd.

www.daiichisankyo.com

Latest From Daiichi Sankyo Co. Ltd.

Ranbaxy Brothers Arrested, Downward Spiral Intensifies

The Singh brothers of Ranbaxy have been arrested over allegations of financial fraud and things appear headed further downhill. Daiichi Sankyo is also separately pursuing enforcement of damages against the brothers.

Commercial India

Asia Deal Watch: Daiichi Sankyo Obtains Brazilian Rights To Mitsubishi Tanabe’s ALS Drug

Daiichi Sankyo also gets right of first negotiation for edaravone, approved in the US and Japan, in other Central and South American markets. Astellas advances its “Rx+” strategy in partnership with iota Biosciences.

Deals Business Strategies

Astellas Stays Ahead of Daiichi Sankyo In AML With CHMP Nod For Xospata

A positive opinion for its FLT3 inhibitor for acute myeloid leukemia gives Astellas a further advantage over its Japanese competitor's same-class offering, quizartinib.

Drug Review Cancer

First Filing, In Japan, For Daiichi’s Lead ADC As Others Progress

In a further positive step for its oncology ambitions, Japanese company files first submission for promising lead antibody-drug conjugate, partnered globally with AstraZeneca, while other pipeline ADCs mark development progress.

Cancer Clinical Trials
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register